login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
CRINETICS PHARMACEUTICALS IN (CRNX) Stock News
USA
- NASDAQ:CRNX -
US22663K1079
-
Common Stock
42.51
USD
-0.34 (-0.79%)
Last: 11/4/2025, 8:14:05 PM
42.51
USD
0 (0%)
After Hours:
11/4/2025, 8:14:05 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
CRNX Latest News, Press Relases and Analysis
All
Press Releases
13 days ago - By: Crinetics Pharmaceuticals, Inc.
Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
13 days ago - By: Crinetics Pharmaceuticals, Inc.
Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
23 days ago - By: Benzinga
- Mentions:
FAST
SLE
FROG
VNCE
...
Fastenal Posts Downbeat Earnings, Joins Vince Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session
a month ago - By: Benzinga
FDA Approves Crinetics Pharma's First Daily Pill For Rare Growth Disorder
a month ago - By: Stocktwits
Retail Chatter Surges As Crinetics Wins FDA Nod For First Oral Acromegaly Drug — Traders Expect Big Price Move
25 days ago - By: Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
25 days ago - By: Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
a month ago - By: Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
a month ago - By: Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
a month ago - By: The Motley Fool
- Mentions:
GS
Is Crinetics Pharmaceuticals Stock a Buy?
a month ago - By: Investor's Business Daily
- Mentions:
AAPL
Crinetics Pharma Surges After FDA OKs Its Treatment For A Form Of Gigantism
a month ago - By: Crinetics Pharmaceuticals, Inc.
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
a month ago - By: Crinetics Pharmaceuticals, Inc.
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
2 months ago - By: Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 months ago - By: Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: Crinetics Pharmaceuticals, Inc.
Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
3 months ago - By: Crinetics Pharmaceuticals, Inc.
Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
3 months ago - By: Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: The Motley Fool
Crinetics (CRNX) Q2 Revenue Jumps 150%
3 months ago - By: Zacks Investment Research
- Mentions:
CASI
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Lags Revenue Estimates
3 months ago - By: Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
3 months ago - By: Yahoo Finance
Crinetics Pharmaceuticals, Inc. (CRNX)’ Oral Acromegaly Drug Nears FDA Decision After Strong Phase 3 Data
4 months ago - By: Yahoo Finance
- Mentions:
GS
Crinetics Pharmaceuticals (CRNX) Gets Initiated With a Hold Rating at Goldman Sachs
4 months ago - By: Stocktwits
- Mentions:
WMT
Crinetics Pharma’s Oral Drug Shows Lasting Relief For Acromegaly Patients In Latest Study; Retail Buzz Builds
4 months ago - By: Crinetics Pharmaceuticals, Inc.
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
Please enable JavaScript to continue using this application.